VISOMITIN® Eye drops are used to treat the initial stage of age-related cataracts and dry eye syndrome. Visomitin has antioxidant and keratoprotective effects. Visomitin® is a mild and therefore slow-acting preparation.

Mitotech is developing several preparation formulations of SkQ1 covering a variety of therapeutic areas and methods of administration. The most advanced SkQ1-based preparation in Mitotech's development is Visomitin®, which reached Phase III stage in the U.S. for Dry Eye Disease. Visomitin® received marketing approval for Dry Eye Disease in Russia. Multifactorial nature of Dry Eye made this indication a perfect target for SkQ1 as molecule’s mechanism of action addresses gland tissue degeneration, cornea/conjunctiva healing rate and inflammation at the same time.

Most cells in our body contain special organelles – mitochondria. They are cellular power plants - they produce and store energy, which is subsequently consumed by the cell.

A by-product of useful energy production is reactive oxygen species (ROS). An excessive amount of ROS leads to the so-called oxidative stress, which causes serious harm to the cell. Although the cell itself has the means to combat excess ROS, in the case of a number of diseases these protective systems do not cope with the task and ROS can trigger the process of programmed cell death (apoptosis), activate inflammatory reactions or cause harm to the body in other ways. Situations in which natural antioxidant defenses are insufficient are more likely to occur as we age.

To combat excess free radicals, special substances – antioxidants – are traditionally used. However, the experience accumulated to date in their use in clinical practice indicates the low effectiveness of conventional antioxidants. There are several reasons for this, but one of the most important is that the preparations do not penetrate the mitochondria. Since mitochondria are the main source of ROS in the cell, it is necessary to deliver significant amounts of the antioxidant to these organelles. The non-targeted preparation will then be distributed throughout the cell and the body, which forces the use of huge doses, most of which do not reach the mitochondria.

“Skulachev ions”, on the basis of which the active substance of the preparation Visomitin® was created, have unique properties: when they enter cells, they accumulate in the mitochondria. Visomitin® is the world's first registered antioxidant that specifically targets mitochondria.

Indications for use:

As part of complex therapy:

• Symptoms of dry eye syndrome / corneal-conjunctival xerosis (poor tolerance to wind, conditioned air, smoke, foreign body sensation, pain, burning, dry eyes, floating visual acuity, lacrimation, redness of the eyes in the area not covered eyelid).
• Symptoms of the initial stage of age-related cataracts (gradual blurring and decreased visual acuity).

Ingredients:

The active substance of VISOMITIN® Eye drops is plastoquinonyldecyltriphenylphosphonium bromide (PDTP), aka SkQ1, at a dosage of 155 ng/ml.
Excipients: Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.0 - 8.0, purified water 1 ml.

Method of application:

Symptoms of the "dry eye" syndrome: 1-2 drops of the preparation in the conjunctival sac 3 times a day. According to clinical studies, the therapeutic effect is achieved in the first 2-4 weeks of use. The therapeutic effect is persistent when used for 6 weeks. If there is no effect during the first two weeks of treatment, a specialist examination is required.

The initial stage of age-related cataract: 1-2 drops of the preparation into the conjunctival sac 3 times a day. The duration of the course of treatment is 6 months. The diagnosis of "the initial stage of age-related cataract" must be established by a specialist. If there is no improvement after treatment, or the symptoms worsen or new symptoms appear, you should consult your doctor.
Use the preparation only according to the indications, the route of administration and the doses indicated in the instructions for use.
One bottle is designed for use 3 times a day, 1-2 drops for 24 days.

Special instructions:

Contact lenses: Visomitin® eye drops contain benzalkonium chloride as a preservative and are not recommended for use when wearing contact lenses. Before instilling eye drops, contact lenses should be removed and put back on no earlier than 15 minutes after using the preparation.
The bottle must be closed after each use.
Do not touch the eye with the tip of the pipette while instilling.
The active ingredient of Visomitin® is very sensitive to light: between uses, do not store the bottle in a lighted place!

Storage conditions:

In a dark place at a temperature from +2 to +8°C.
Store the opened bottle in a dark place at a temperature from +2 to +8°C; use within 1 month.
Keep out of the reach of children!

Interaction with other preparations:

There have been no previously reported adverse interactions between Visomitin® and other preparations. If necessary, it can be used simultaneously with other eye drops;
the interval between instillations should be at least 15 minutes.

Contraindications:

Hypersensitivity to the components of the preparation.
Children under 18 years of age (no clinical trial data available).

Contains:

5 ml

Guaranteed authenticity and quality:

100% Original from the MITOTECH With the direct participation of Lomonosov Moscow State University (Russia)

Development and production:

The active substance - the SkQ1 molecule was developed at Moscow State University. It combines many years of work by biologists and the power of the most powerful antioxidant from plant chloroplasts - plastoquinone. The special structure of the SkQ1 antioxidant, including the Skulachev ion, allows the molecule to penetrate into the most inaccessible place inside the cell - into the mitochondria, where it neutralizes excess free radicals, thereby slowing down the development of age-related skin changes at the intracellular level.

Developed by MITOTECH company together with the Moscow State University.

Produced by FIRN M company by order of MITOTECH (Russia, Moscow).

The biotech company FIRN M was created at the USSR Academy of Sciences in 1989. The company's main activity is the development and production healing preparations. Today, FIRN M is one of the most dynamically developing biotech companies in Russia. The company occupies a leading position in the Russian market for the development and production of ophthalmological preparations.